One Bioscience raises €15m to leverage AI tumour profiling

One Biosciences strengthens its position as precision oncology innovator with €15 million Series A financing round to accelerate the clinical application of its flagship technology, OneMap™. The financing, led by Redmile Group and Blast, with strong support from a diverse group of investors including Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures, brings the company’s total funding to over €20 million.

Founded in 2020 by Dr Céline Vallot (Curie Institute) and Home Biosciences, One Biosciences is emerging as a key European player in clinical-grade single-cell transcriptomic profiling, a next-generation approach to understanding tumour biology at unprecedented resolution. Building on the innovative research of Dr. Céline Vallot, CNRS research director and head of the “Dynamics of Epigenetic Plasticity in Cancer” team at Institut Curie, the start-up uses single-cell profiling to improve cancer diagnosis and guide therapeutic decisions. Supported since 2019 as part of Institut Curie’s incubation program, One Biosciences has received tailored guidance, from its earliest stages through its operational development. Its platform, OneMap™, combines deep single-cell data with proprietary AI algorithms to deliver functional tumour maps that can guide treatment decisions, support therapy development, optimise clinical trials, and enable more precise patient stratification. Tumour heterogeneity remains one of the biggest challenges in cancer. As a techbio company, One Biosciences brings AI-powered single-cell analysis into clinical practice, transforming how cancer is understood and treated by generating detailed functional tumour profiles.

The company’s vision is to transform cancer care by decoding tumour heterogeneity from routine clinical samples. By doing so, One Biosciences enables physicians to tailor therapies more effectively, and provides pharmaceutical partners with actionable insights to improve trial design and drug development pipelines.

As CEO Hedi Ben Brahim explains: “This funding enables us to translate our breakthrough single-cell technology into real-time clinical insights. By supporting physicians and drug developers alike, we hope to accelerate access to more effective and personalised therapies.” Co-founder Dr Céline Vallot adds: “With this investment and our proprietary single-cell datasets, we can further refine our AI models to predict treatment responses across multiple oncology drug classes.”

Strategic Partnerships and Expansion

One Biosciences collaborates with leading French institutions such as the Curie Institute, Gustave Roussy, and AP-HP, and is supported by national initiatives including France 2030, Medicen, PSCC, and Matwin. The company plans to use the Series A proceeds not only to advance clinical validation of OneMap™, but also to scale strategic partnerships with pharmaceutical and biotech companies globally.

Dr Mehdi Touat, Assistant Professor at AP-HP and the Paris Brain Institute, highlights the promise of this approach: “While next-generation sequencing has improved cancer diagnostics, its clinical utility remains limited. Clinical-grade single-cell profiling like OneMap™ could enable the next leap in personalised oncology.”

With its growing team, strong scientific foundation, and backing from top-tier investors, One Biosciences is positioning itself as a European leader in AI-driven precision oncology. The company’s strategy—anchored in clinical relevance, technological innovation, and collaborative growth—aims to set new standards for how complex tumour data can be leveraged for better outcomes in cancer treatment and drug development.